{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:14:27Z","timestamp":1790644467762,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Mantle cell lymphoma (MCL) is a rare aggressive variant of non-Hodgkin lymphoma. Clinical and survival data from India are scarce.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>\n              We retrospectively analyzed clinicopathologic data of 98 patients with MCL treated at our center in the past 10 years. STATA 13.0 was used for overall survival (OS) and event-free survival (EFS) assessment by Kaplan-Meier analysis. Univariate and multivariate analyses (Cox proportional hazards) were used to identify predictors of survival.\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              value &lt; .05 defined statistical significance.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              Median age was 60.0 years. There was extranodal involvement in 77\/98 (79.0%) patients. Ninety-one of 98 (93.0%) and 54\/97 (56.0%) patients, respectively, were in advanced stage (III\/IV) and high-risk MCL International Prognostic Index score at presentation. There was bulky disease in 19\/98 (19.0%) patients. Classical histology and interstitial\/paratrabecular bone marrow (BM) infiltration was most frequent. Sixteen percent had BM without peripheral blood involvement. Most patients, 83\/96 (86.0%), received rituximab-based induction chemotherapy. Fifty-one of 96 (53.0%) patients were alive with a median follow-up of 63.0 months. Median OS was 43.0 months. Estimated 3.0-year OS and EFS were 60.0% and 35.0%, respectively. Rituximab maintenance (RM) improved both OS (\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt; .01) and EFS (\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt; .01). Median OS was lower in the non-RM group (37.0 months\n              <jats:italic toggle=\"yes\">v<\/jats:italic>\n              not reached; adjusted hazard ratio, 0.31 [95% CI, 0.13 to 0.72],\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt; .01). Age &gt;60 years, Eastern Cooperative Oncology Group performance status \u22652, advanced stage, and leukocytosis at presentation were associated with poor OS.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Our study was a comprehensive analysis of patients with MCL from India. To our knowledge, this was the first study of its kind demonstrating OS and EFS benefit of RM in MCL from this part of the world.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/go-24-00654","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:59:14Z","timestamp":1758311954000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Clinicopathologic Characteristics and Survival Outcome of Patients With Mantle Cell Lymphoma: A North Indian Tertiary Care Center Experience"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1075-2988","authenticated-orcid":true,"given":"Soumyadeep","family":"Datta","sequence":"first","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6500-1061","authenticated-orcid":true,"given":"Ajay","family":"Gogia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr B.R. Ambedkar - Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr B.R. Ambedkar - Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveet","family":"Wig","sequence":"additional","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-4086","authenticated-orcid":true,"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Laboratory Oncology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9719-9380","authenticated-orcid":true,"given":"Hari Krishna Raju","family":"Sagiraju","sequence":"additional","affiliation":[{"name":"Department of Preventive Oncology, National Cancer Institute\u2014All India Institute of Medical Sciences, Jhajjar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4366-5873","authenticated-orcid":true,"given":"Saumyaranjan","family":"Mallick","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.4103\/sajc.sajc_60_18"},{"key":"e_1_3_7_3_2","volume-title":"SEER Cancer Statistics Review, 1975-2015","author":"Howlader N","year":"2013","unstructured":"Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2015. National Cancer Institute, Bethesda, MD, 2013"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-021-00683-2"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65399-0"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2019.04.010"},{"key":"e_1_3_7_7_2","first-page":"16534","article-title":"Clinicopathological and immunohistochemical profile of mantle cell lymphoma: An institutional experience","volume":"13","author":"Mishra P","year":"2021","unstructured":"Mishra P, Padhi S, Ayyanar P, et al: Clinicopathological and immunohistochemical profile of mantle cell lymphoma: An institutional experience. Cureus 13:16534, 2021","journal-title":"Cureus"},{"key":"e_1_3_7_8_2","first-page":"4583","article-title":"Mantle cell lymphoma: A north Indian tertiary care centre experience","volume":"17","author":"Das CK","year":"2016","unstructured":"Das CK, Gogia A, Kumar L, et al: Mantle cell lymphoma: A north Indian tertiary care centre experience. Asian Pac J Cancer Prev 17:4583-4586, 2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010264"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001233"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.7.2715.2715"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201817"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_3_7_18_2","first-page":"67","article-title":"Zanubrutinib in mantle cell lymphoma management: A comprehensive review","volume":"13","author":"Alsuhebany N","year":"2023","unstructured":"Alsuhebany N, Pan C, Holovac E, et al: Zanubrutinib in mantle cell lymphoma management: A comprehensive review. Blood Lymphat Cancer 13:67-76, 2023","journal-title":"Blood Lymphat Cancer"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30685-5"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/11204940-000000000-00000"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01797"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg414"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236570"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2067"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/11.suppl_1.S63"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2002317"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001278"},{"key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"e0225096","DOI":"10.1371\/journal.pone.0225096","article-title":"Diagnostic accuracy of SOX11 immunohistochemistry in mantle cell lymphoma: A meta-analysis","volume":"14","author":"Lee W","year":"2019","unstructured":"Lee W, Shin E, Kim BH, et al: Diagnostic accuracy of SOX11 immunohistochemistry in mantle cell lymphoma: A meta-analysis. PLoS One 14:e0225096, 2019","journal-title":"PLoS One"},{"key":"e_1_3_7_32_2","first-page":"1726","article-title":"The clinical-biological features and prognosis of patients with mantle cell lymphoma","volume":"31","author":"Chen WZ","year":"2023","unstructured":"Chen WZ, Liu TB.: The clinical-biological features and prognosis of patients with mantle cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 31:1726-1732, 2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-24-00654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:59:25Z","timestamp":1758311965000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-24-00654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1200\/GO-24-00654"],"URL":"https:\/\/doi.org\/10.1200\/go-24-00654","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2024-12-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400654"}}